Canada: Pharmacapsules - November 2004

Last Updated: November 17 2004

Edited by Adrienne Blanchard and Jennifer Wilkie


  • Canada And U.S. Cooperate On Competition Law Enforcement
  • Physician Survey Identifies Future Supply And Access Problems
  • Generic Manufacturer May Fund Internet Pharmacy Association
  • C.D. Howe Institute Says "Close Internet Pharmacies"
  • Missouri Adopts Illinois' Internet Pharmacy Program
  • Illinois Governor Seeks Flu Vaccine Outside United States
  • Improved Patient Safety Priority For World Health Organization
  • European Commission Proposes Regulations For Compulsory Licenses For Medicines

Canada And U.S. Cooperate On Competition Law Enforcement

Canada and the U.S. have signed a "Comity" Agreement to enhance cooperation between their respective antitrust/competition enforcement agencies. The Agreement seeks to minimize duplicative and sometimes conflicting enforcement efforts. It establishes a formal mechanism whereby Canada can request that the U.S. investigate and take action against civil anti-competitive activities occurring principally in the U.S. that have an impact in Canada. Equally, the U.S. can seek similar assistance with respect to civil anti-competitive activities occurring principally in Canada that have a cross border effect.

While the Agreement is meant to promote cooperation in certain circumstances, it does not impose any positive obligations to investigate a complaint from their neighbour on either Canada or the U.S.

Under the terms of the Agreement, neither country is precluded from initiating its own investigation and enforcement action even if similar procedures are already underway in the other country. However, in certain circumstances, Canada and the U.S. can defer or suspend their own enforcement actions and let the other country, where the anti-competitive practices are principally occurring, investigate and remedy them.

The Agreement dovetails into the previous 1995 Canada-U.S. cooperation agreement that provided for mutual notification and coordination of enforcement activities in specific circumstances. The 1995 Agreement deals with how and when the two countries will help each other with their respective civil investigations. This new Agreement goes one step further in that it closely mirrors a comity agreement signed by the U.S. and the European Community in 1998.

The text of the Agreement can be viewed at:

For further information on this and other competition law issues, contact Bill Vanveen or Francois Baril.

Physician Survey Identifies Future Supply And Access Problems

A survey of more than 21,000 physicians, conducted by the College of Family Physicians of Canada, the Canadian Medical Association, and the Royal College of Physicians and Surgeons of Canada, shows that access to care and wait times for Canadians is due to a low physician supply. Sixty percent of family physicians are either limiting the number of new patients they see or are not taking new patients at all. A third of specialists said the wait time for non-urgent cases referred to them was greater than three months. Further, a large number of physicians are reaching retirement and women, who make up over half of all new physicians coming out of medical school, on average work about seven fewer hours a week than their male colleagues. The profound changes to the health-care system produced by these shifts will have to be addressed by governments, according to a Canadian Medical Association spokesperson.

Further information may be found at:

Generic Manufacturer May Fund Internet Pharmacy Association

An e-mail obtained by the media suggests that a generic drug manufacturer, Apotex, has discussed offering money to a group representing Internet pharmacies in exchange for increased sales of its products. An International Pharmacy Association spokesperson said that discussions with the generic company are ongoing that the Internet Pharmacy Association is "seeking any opportunity we can for funding."

A spokesman for the company denied that it was in negotiations with the Internet pharmacy group. A spokesman for Rx&D, the association that represents innovative companies in Canada, stated that legal questions about patent infringement are raised by the sale of some generics into the U.S. market and that "the generics appear to be associating themselves with a business that has questionable ethics in terms of the relationship between the health-care professional and the patients."

For more information, please see:

C.D. Howe Institute Says "Close Internet Pharmacies"

A study released by the C.D. Howe Institute says that Canada's Internet pharmacies represent a threat to domestic drug supplies and prices, and that the federal government should act now to close these businesses.

The authors of the study say that Canada has not to date suffered a serious shortage of drugs or big price increases because the cross-border trade remains mostly illegal and the volume small. However, they warn that this situation could quickly change if legislation is passed in Washington to legalize imports. The study states that the Canadian government should act sooner rather than later to shut down the cross-border trade. Acting now would be consistent with the current U.S. FDA policy, which prohibits imports of drugs from Canada. If, however, the next President implements legislation to facilitate drug imports, "it would look hostile on Canada's part to immediately prohibit drug exports."

A news article written by an author of the study can be found at:

The study is located at:

Missouri Adopts Illinois' Internet Pharmacy Program

Missouri Governor Bob Holden announced that Missourians can immediately start participating in Illinois' new mail-order system for buying prescription drugs from a provider in Canada, namely CanaRx Services Inc. of Hamilton, Ontario. The Missouri governor made the announcement alongside Illinois Governor Rod Blagojevich, who promoted the idea and opened the system, known as I-SaveRx, for business on October 4, 2004. Governor Holden stated that the I-SaveRx system allows people without insurance to take advantage of cheaper drug prices in Canada, Ireland and the United Kingdom. In doing so, Missouri brushed aside the U.S. FDA's opposition to the I-SaveRx system, which it considers a violation of federal law that restricts importation of drugs.

For more information, please see:

Illinois Governor Seeks Flu Vaccine Outside United States

Illinois Governor Rod R. Blagojevich, one of several leaders of state efforts to buy prescription drugs from outside the United States, including from Canada, recently detailed that he has secured at least 30,000 doses of flu vaccine in conversations with European drug wholesalers. The Governor wants permission from the U.S. FDA to buy the doses for residents of Illinois. He requested that the federal Center for Disease Control (CDC) allow Illinois to use federal funds to purchase the extra doses, but stated that if the CDC refuses, the state will cover all of the costs itself.

For more information, please see:

Improved Patient Safety Priority For World Health Organization

The World Health Organization (WHO), along with a global group of ministers of health and senior officials, academics and patients' groups, has announced the launch of the World Alliance for Patient Safety. The Alliance plans to reduce the adverse health and social consequences of health care, by taking steps to cut the number of illnesses, injuries and deaths suffered by patients using clinics and hospitals. Dramatic decreases in adverse effects in health care and declines in expenditure are expected as a result of the Alliance's strategies. Issues such as research developments, delivery issues and knowledge on a worldwide scale will be undertaken by political leaders in several countries.

Further information may be found at:

European Commission Proposes Regulations For Compulsory Licenses For Medicines

The European Commission has proposed a Regulation to allow manufacturers of generic pharmaceuticals to produce patented medicines for export to "countries in need" who do not have sufficient capacity to produce them. The Regulation would implement the August 30, 2003, World Trade Organization (WTO) Decision. Under the Regulation national authorities in the European Union can grant compulsory licences for such production if certain conditions are fulfilled. National laws do not allow compulsory licences for export since the WTO TRIPS Agreement allows compulsory licences to be issued only if they are "predominantly for the supply of the domestic market." The WTO Decision addressed the difficulties raised by this restriction by waiving this obligation.

For more information, please see:

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions